Comparable stake leader
PharmaCyte Biotech, Inc.
SEC ownership of Q/C TECHNOLOGIES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001321834.
Disclosed value leader
PharmaCyte Biotech, Inc.
Comparable rows
18/32
Latest evidence
13 Apr 2026
- Public ticker
- QCLS on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PharmaCyte Biotech, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
18 of 32
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PharmaCyte Biotech, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
13 Apr 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001321834
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Q/C TECHNOLOGIES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PharmaCyte Biotech, Inc.
Disclosed value leader
PharmaCyte Biotech, Inc.
Comparable rows
18/32
Latest evidence
13 Apr 2026
13D/G
3/4/5
13F
Lead comparable stake: 74%
14 rows are not safely comparable across share classes.
13D/G row: PharmaCyte Biotech, Inc.
Showing 1-8 of 32 holder rows.
Quick read
PharmaCyte Biotech, Inc. leads the comparable SEC ownership view at 74%.
18 of 32 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PharmaCyte Biotech, Inc.'s linked filing trail.
Comparable ownership
Top 5
PharmaCyte Biotech, Inc.
74%
Quinn Opportunity Partners LLC
1.8%
JANE STREET GROUP, LLC
1.1%
UBS Group AG
0.68%
ADAR1 Capital Management, LLC
0.44%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 32 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. |
13D/G
3/4/5
10%+ Owner
|
74%
|
$28,646,744
8,475,368 shares
|
$0 | 14 Nov 2025 |
| Quinn Opportunity Partners LLC |
13F
Company
|
1.8%
|
$729,296
211,390 shares
|
— | 31 Mar 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
1.1%
|
$435,348
126,188 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.68%
|
$269,062
77,989 shares
|
— | 31 Mar 2026 |
| ADAR1 Capital Management, LLC |
13F
Company
|
0.44%
|
$172,500
50,000 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.41%
|
$163,495
47,390 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.33%
|
$129,413
37,511 shares
|
— | 31 Mar 2026 |
| HRT FINANCIAL LP |
13F
Company
|
0.2%
|
$77,000
22,404 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$5,522.
Buys
$5,522
Insiders: 1
Sells
$0
Insiders: 0
Net
+$5,522
Shares: +1,753
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,753
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 1,753 | 0 | $5,522 | $0 | +$5,522 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Q/C TECHNOLOGIES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Chelsea Sierra Voss
Net 12M change
+$5,522
Latest report
13 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chelsea Sierra Voss | Director | $1,059,937 | +$5,522 | +0.52% | Mixed | 13 Apr 2026 |
| Joshua Silverman | Executive Chairman, Director | $1,046,142 | Mixed | 13 Apr 2026 | ||
| Paul Rivard | Chief Legal Officer | $444,000 | Filing P/S | 24 Aug 2023 | ||
| Bruce Bernstein | Director | $108,750 | Mixed | 13 Apr 2026 | ||
| Stephen Friscia | Director | $108,750 | Mixed | 13 Apr 2026 | ||
| Billy Joe White | Director | $84,581 | Mixed | 13 Apr 2026 | ||
| Gary M. Rauch | Vice President of Finance | $54,375 | Mixed | 14 Nov 2025 | ||
| Mitchell Glass | Chief Medical Officer, Director | $42,250 | Mixed | 13 Apr 2026 | ||
| Craig Eagle | Director | Mixed | 07 Jun 2023 | |||
| Adam Kaplin | Chief Scientific Officer | Mixed | 07 Jun 2023 | |||
| Christopher Chapman MD | President, Chief Med. Officer, Director | Mixed | 07 Jun 2023 | |||
| Jude Uzonwanne | Director | Mixed | 07 Jun 2023 | |||
| Christopher C. Schreiber | Director | Mixed | 07 Jun 2023 | |||
| PharmaCyte Biotech, Inc. | 10%+ Owner | Mixed | 04 Sep 2025 | |||
| Ian Thomas Rhodes | Interim CFO | Mixed | 17 Apr 2025 |
Recent insider transactions for Q/C TECHNOLOGIES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Chelsea Sierra Voss | QCLS | Employee Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Stephen Friscia | QCLS | Employee Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Billy Joe White | QCLS | Employee Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Mitchell Glass | QCLS | Employee Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Joshua Silverman | QCLS | Common stock | Award | 162.1% | 162,162 | 262,191 | 13 Apr 2026 | Direct | ||
| Joshua Silverman | QCLS | Employee Stock Option (Right to Buy) | Award | 100,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Bruce Bernstein | QCLS | Employee Stock Option (Right to Buy) | Award | 50,000 | 50,000 | 13 Apr 2026 | Direct | |||
| Chelsea Sierra Voss | QCLS | Common stock | Purchase | 2.93% | $5,522 | $3.15 | 1,753 | 61,555 | 30 Mar 2026 | By Roth IRA |
| Chelsea Sierra Voss | QCLS | Common stock | Award | 9895.8% | 237,500 | 239,900 | 16 Jan 2026 | Direct | ||
| Chelsea Sierra Voss | QCLS | Employee Stock Option (Right to Buy) | Award | 212,500 | 212,500 | 16 Jan 2026 | Direct | |||
| PharmaCyte Biotech, Inc. | TNFA | Warrants | Purchase | 889,865 | 889,865 | 14 Nov 2025 | Direct | |||
| Mitchell Glass | TNFA | Common stock | Award | 1057.4% | 11,420 | 12,500 | 14 Nov 2025 | Direct | ||
| Billy Joe White | TNFA | Common stock | Award | 1045.3% | 22,839 | 25,024 | 14 Nov 2025 | Direct | ||
| Joshua Silverman | TNFA | Common stock | Award | 1053.3% | 91,356 | 100,029 | 14 Nov 2025 | Direct | ||
| Stephen Friscia | TNFA | Common stock | Award | 1056.9% | 22,839 | 25,000 | 14 Nov 2025 | Direct | ||
| Bruce Bernstein | TNFA | Common stock | Award | 25,000 | 25,000 | 14 Nov 2025 | Direct | |||
| Gary M. Rauch | TNFA | Common stock | Award | 1057.4% | 11,420 | 12,500 | 14 Nov 2025 | Direct | ||
| Joshua Silverman | TNFA | Common stock | Award | 29806.9% | 8,644 | 8,673 | 03 Oct 2025 | Direct | ||
| Stephen Friscia | TNFA | Common stock | Award | 2,161 | 2,161 | 03 Oct 2025 | Direct | |||
| Mitchell Glass | TNFA | Common stock | Award | 1,080 | 1,080 | 03 Oct 2025 | Direct | |||
| Billy Joe White | TNFA | Common stock | Award | 9004.2% | 2,161 | 2,185 | 03 Oct 2025 | Direct | ||
| Gary M. Rauch | TNFA | Common stock | Award | 1,080 | 1,080 | 03 Oct 2025 | Direct | |||
| PharmaCyte Biotech, Inc. | TNFA | Series H Convertible Preferred Stock | Purchase | 889,865 | 889,865 | 04 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.